Terms: = Endocrine gland cancer AND TGFBR2, AAT3, 7048, ENSG00000163513, P37173, TGFbeta-RII, RIIC, TAAD2, FAA3, TGFR-2, MFS2, HNPCC6 AND Treatment
14 results:
1. Modulatory effect of pomegranate peel extract on key regulators of ovarian cellular processes
Kolesarova A; Baldovska S; Kohut L; Vasicek J; Ivanisova E; Arvay J; Duracka M; Roychoudhury S
Front Endocrinol (Lausanne); 2023; 14():1277155. PubMed ID: 38027211
[TBL] [Abstract] [Full Text] [Related]
2. Dysregulation of the circ_0087502/miR-1179/tgfbr2 pathway supports gemcitabine resistance in pancreatic cancer.
Chen M; Liu X; Lu J; Teng H; Yu C; Liu Y; Zheng Y
Cancer Biol Ther; 2023 Dec; 24(1):2258566. PubMed ID: 37844011
[TBL] [Abstract] [Full Text] [Related]
3. Unraveling the Roles of miR-204-5p and HMGA2 in Papillary Thyroid cancer Tumorigenesis.
Van Branteghem C; Augenlicht A; Demetter P; Craciun L; Maenhaut C
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445942
[TBL] [Abstract] [Full Text] [Related]
4. USP33 promotes pancreatic cancer malignant phenotype through the regulation of tgfbr2/TGFβ signaling pathway.
Liu X; Xu J; Shen B; Xu J; Jiang J
Cell Death Dis; 2023 Jun; 14(6):362. PubMed ID: 37322017
[TBL] [Abstract] [Full Text] [Related]
5. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study.
de Castro Silva I; Bianchi A; Deshpande NU; Sharma P; Mehra S; Garrido VT; Saigh SJ; England J; Hosein PJ; Kwon D; Merchant NB; Datta J
Elife; 2022 Sep; 11():. PubMed ID: 36107485
[TBL] [Abstract] [Full Text] [Related]
6. CRISPR-mediated tgfbr2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Fix SM; Forget MA; Sakellariou-Thompson D; Wang Y; Griffiths TM; Lee M; Haymaker CL; Dominguez AL; Basar R; Reyes C; Kumar S; Meyer LA; Hwu P; Bernatchez C; Jazaeri AA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35882447
[TBL] [Abstract] [Full Text] [Related]
7. Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic cancer.
Dosch AR; Singh S; Dai X; Mehra S; Silva IC; Bianchi A; Srinivasan S; Gao Z; Ban Y; Chen X; Banerjee S; Nagathihalli NS; Datta J; Merchant NB
Mol Cancer Ther; 2021 Nov; 20(11):2280-2290. PubMed ID: 34518296
[TBL] [Abstract] [Full Text] [Related]
8. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract] [Full Text] [Related]
9. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract] [Full Text] [Related]
10. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract] [Full Text] [Related]
11. Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells.
Kohan-Ivani K; Gabler F; Selman A; Vega M; Romero C
J Cancer Res Clin Oncol; 2016 Jan; 142(1):47-58. PubMed ID: 26091707
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer.
Takahashi R; Hirata Y; Sakitani K; Nakata W; Kinoshita H; Hayakawa Y; Nakagawa H; Sakamoto K; Hikiba Y; Ijichi H; Moses HL; Maeda S; Koike K
Cancer Sci; 2013 Mar; 104(3):337-44. PubMed ID: 23237571
[TBL] [Abstract] [Full Text] [Related]
13. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, tgfbeta-rii, KRAS2, TP53 and/or CDNK2A.
Samouëlian V; Maugard CM; Jolicoeur M; Bertrand R; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Chemother Pharmacol; 2004 Dec; 54(6):497-504. PubMed ID: 15258697
[TBL] [Abstract] [Full Text] [Related]
14. [Medullary carcinoma of the thyroid gland (sporadic, familial)].
Paunović I; Diklić A; Krgović K; Zivaljević V; Tatić S; Havelka M; Kalezić N; Todorovic-Kazić M; Bozić V
Acta Chir Iugosl; 2003; 50(3):113-20. PubMed ID: 15179766
[TBL] [Abstract] [Full Text] [Related]
